Zacks: Brokerages Anticipate Neon Therapeutics Inc (NTGN) Will Post Earnings of -$0.76 Per Share
Equities research analysts forecast that Neon Therapeutics Inc (NASDAQ:NTGN) will post ($0.76) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Neon Therapeutics’ earnings. The highest EPS estimate is ($0.66) and the lowest is ($0.84). Neon Therapeutics reported earnings of ($7.84) per share in the same quarter last year, which would indicate a positive year over year growth rate of 90.3%. The business is expected to report its next quarterly earnings results on Monday, August 5th.
According to Zacks, analysts expect that Neon Therapeutics will report full-year earnings of ($2.70) per share for the current year, with EPS estimates ranging from ($3.33) to ($1.83). For the next year, analysts expect that the company will post earnings of ($2.80) per share, with EPS estimates ranging from ($4.26) to ($1.96). Zacks’ EPS averages are an average based on a survey of research firms that cover Neon Therapeutics.
Neon Therapeutics (NASDAQ:NTGN) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.76) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by ($0.03).
NTGN opened at $5.60 on Monday. The stock has a market capitalization of $153.27 million and a P/E ratio of -1.01. Neon Therapeutics has a 12 month low of $4.20 and a 12 month high of $16.23.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTGN. Hillhouse Capital Advisors Ltd. bought a new stake in Neon Therapeutics in the fourth quarter worth about $1,572,000. FMR LLC lifted its stake in Neon Therapeutics by 1.1% in the fourth quarter. FMR LLC now owns 2,079,669 shares of the company’s stock worth $10,461,000 after purchasing an additional 23,075 shares during the last quarter. BlackRock Inc. lifted its stake in Neon Therapeutics by 12.0% in the fourth quarter. BlackRock Inc. now owns 307,782 shares of the company’s stock worth $1,548,000 after purchasing an additional 32,943 shares during the last quarter. Vanguard Group Inc. lifted its stake in Neon Therapeutics by 215.9% in the third quarter. Vanguard Group Inc. now owns 197,414 shares of the company’s stock worth $1,686,000 after purchasing an additional 134,914 shares during the last quarter. Finally, Vanguard Group Inc lifted its stake in Neon Therapeutics by 215.9% in the third quarter. Vanguard Group Inc now owns 197,414 shares of the company’s stock worth $1,686,000 after purchasing an additional 134,914 shares during the last quarter. Institutional investors own 70.50% of the company’s stock.
About Neon Therapeutics
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Read More: What are earnings reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.